DRUG · Unmapped registry intervention
PRT3789
Find medicine records ·
Find other trials using this name
Clinical trial
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
NCT05639751
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Advanced Solid Tumorunresolved
Metastatic Solid Tumorunresolved
Non-small Cell Lung Cancersunresolved
SMARCA4 Gene Mutationunresolved
Interventions
PRT3789DRUG
DocetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
Prelude Therapeutics Incorporatedlead sponsor
Mapped research locations
New YorkNew York, United States3BostonMassachusetts, United States2ClevelandOhio, United States2MadridMadrid, Spain2HoustonTexas, United States1ChicagoIllinois, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1BarcelonaSpain1PortlandOregon, United States1JacksonvilleFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05639751 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.